Kempharm, inc (KMPH)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-17,985

-24,522

-23,668

-41,802

-42,538

-56,466

-61,849

-56,759

-53,283

-43,386

-42,756

-46,189

-29,904

-16,516

-15,783

-12,114

-51,624

-54,664

-57,301

-54,695

-28,524

-24,455

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Gain on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,740

0

0

0

-

-

-

-

-

-

-

-

Write-off of deferred offering costs

-

116

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

4,149

4,410

4,914

6,443

6,504

6,495

6,395

4,967

4,754

4,562

4,454

6,575

6,667

6,600

6,471

3,684

3,300

2,369

1,501

1,061

279

214

0

0

0

Non-cash interest expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

2,197

2,222

2,222

1,650

1,999

2,285

2,222

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

Amortization of debt issuance costs and debt discount

1,922

1,656

1,493

1,448

1,533

1,618

1,496

1,561

1,561

1,561

1,562

1,561

1,564

1,616

1,700

1,790

1,874

1,909

1,912

1,909

1,591

1,114

0

0

0

Depreciation and amortization expense

298

304

308

311

319

324

330

338

339

336

329

284

229

175

120

99

90

84

80

77

76

75

0

0

0

Fair value adjustment related to derivative and warrant liability

-1,620

-1,998

-7,470

-10,587

-16,170

-5,976

421

3,577

5,616

3,091

-342

2,269

-14,971

-32,465

-28,978

-28,188

15,236

27,276

29,733

29,834

8,743

7,223

0

0

0

Change in estimated deferred offering costs

-

116

0

0

0

-

-

-

-

-

-

-

-

445

0

0

0

-

-

-

-

-

-

-

-

Loss on sublease and disposal of property and equipment

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in assets and liabilities:
Accounts and other receivables

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

-793

-544

-1,832

-1,216

-1,308

548

1,163

1,805

2,370

926

504

65

560

-2,018

-1,147

272

-1,174

1,228

-483

-1,460

-447

-523

0

0

0

Operating lease right-of-use assets

-334

1,537

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-2,176

-3,789

-13,488

-8,097

-3,930

-1,635

6,054

5,580

3,334

-801

-341

-507

-1,070

1,118

946

2,797

1,613

1,315

370

-1,831

-632

933

0

0

0

Operating lease liabilities

-400

2,185

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-7

-798

-804

-839

-857

-102

-110

-75

-15

77

231

253

241

184

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-14,693

-23,737

-35,637

-49,362

-51,170

-54,203

-46,141

-40,357

-37,678

-33,100

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-20,134

-

-20,828

-20,103

-17,782

-14,671

0

0

0

Purchases of property and equipment

20

26

0

0

0

-

-

-

-

181

267

567

676

643

594

314

180

135

123

76

64

47

0

0

0

Purchases of marketable securities and long-term investments

-

-

-

-

-

-

-

-

-

27,378

36,355

45,144

86,853

89,849

0

0

0

-

-

-

-

-

-

-

-

Maturities of marketable securities

-

3,260

11,239

11,702

27,384

33,353

41,426

47,076

46,729

54,971

59,757

66,806

62,116

44,645

0

0

0

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-20

3,234

11,203

11,664

27,346

33,332

35,384

40,582

30,939

27,412

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from equity line of credit

3,837

5,446

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of obligations under capital lease

-

-

-

-

-

193

180

174

169

157

148

141

108

79

58

32

32

32

31

30

31

31

0

0

0

Proceeds from at-the-market offering, net of commissions

-

-

-

-

-

-

-

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt and stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

983

0

0

0

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Repayment of principal on finance lease liabilities

214

207

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt issuance costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-33,848

-

-125

-76

-64

-47

0

0

0

Proceeds from issuance of debt, net of discounts and commissions

-

-

-

-

-

-

-

-

-

-

-

-

-

82,800

0

0

0

-

-

-

-

-

-

-

-

Repayment of term notes and related accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

18,621

0

0

0

-

-

-

-

-

-

-

-

Payment of deferred offering costs

-

-

-

-

-

-

-

-

-

50

174

214

190

164

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of common stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

141

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

3,289

4,939

28,554

27,899

27,940

28,019

4,716

3,886

2,609

-203

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-11,424

-15,564

4,120

-9,799

4,116

7,148

-6,041

4,111

-4,130

-5,891

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of line of credit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35

0

0

0

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

121,046

-

60,940

61,447

27,060

23,004

0

0

0

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

67,064

-

39,987

41,268

9,214

8,286

0

0

0

Supplemental cash flow information:
Cash paid for interest

3,127

5,362

4,861

5,131

5,208

5,539

5,525

5,723

5,718

5,717

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

0

-

0

0

0

-

-

-

-

-

-

-

-

85

0

0

0

-

-

-

-

-

-

-

-

Trade date receivables

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid offering costs charged to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,143

3,276

0

0

0

-

-

-

-

Commitment shares issued in connection with equity line of credit included in deferred offering costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment financed under a lease agreement

-

-

-

-

-

-

-

-

-

284

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

3

0

0

0

Transfer of warrants to equity upon exercise

-

-

-

-

-

-

-

-

-

-

-

-

-

755

0

0

0

-

-

-

-

-

-

-

-

Property and equipment included in accounts payable and accrued expenses

0

-

-

-

-

-

-

0

0

-

-

238

271

281

0

0

0

-

-

-

-

-

-

-

-

The 2021 Notes Converted to Common Stock [Member]
2019 Notes principal converted to common stock

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-